PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients

摘要: The urokinase plasminogen activator (uPA) and the inhibitor 1 (PAI-1) are associated with an aggressive course in breast cancer used to determine whether chemotherapy is needed node-negative patients. objective of study was evaluate prognostic value uPA PAI-1 protein expression advanced patients treated trastuzumab. Formalin-fixed paraffin-embedded tumor tissue samples were retrospectively collected from 230 trastuzumab 130 1st line taxanes. uPA, PAI-1, ER, PgR, HER2 Ki67 evaluated by immunohistochemistry. Central review status revealed that only 144 (63 %) trastuzumab-treated truly HER2-positive. Median survival 50.7 months for HER2-positive 30.1 months HER2-negative (p = 0.006) trastuzumab. In multivariate Cox regression analysis cohort, a significant interaction found, terms survival, between stroma (Wald’s p = 0.002). Positive lower risk death (HR 0.35, 95 % CI 0.19–0.65, Wald’s p = 0.0008). Such association not observed or non-trastuzumab (validation) cohorts. Our results suggest positive stromal may identify subgroup who might benefit treatment Further studies warranted validate these findings larger